Quinoxaline derivatives as adenosine receptor antagonists

1. A compound of formula I,

wherein

Q, Y are independently of one another CH or N,

R 1 is Hal or linear or branched alkyl having 1-10 C atoms which is unsubstituted or mono-, di- or trisubstituted by R 4 and in which 1-4 C atoms may be replaced, independently of one another, by O, S, SO, SO 2 , NH, NCH 3 , —OCO—, —NHCONH—, —NHCO—, —NR 5 SO 2 R 6 —, —COO—, —CONH—, —NCH 3 CO—, —CONCH 3 —, —C≡C— groups and/or —CH═CH— groups, and/or 1-10 H atoms may be replaced by F and/or Cl, or mono- or bicyclic cyclic alkyl having 3-7 C atoms which is unsubstituted or mono-, di- or trisubstituted by R 4 and in which 1-4 C atoms may be replaced, independently of one another, by O, S, SO, SO 2 , NH, NCH 3 , —OCO—, —NHCONH—, —NHCO—, —NR 5 SO 2 R 6 —, —COO—, —CONH—, —NCH 3 CO—, —CONCH 3 —, —C≡C— groups and/or by —CH═CH— groups and/or 1-10 H atoms may be replaced by F and/or Cl, or mono- or bicyclic heteroaryl, heterocyclyl, aryl or cyclic alkylaryl containing 3 to 14 carbon atoms and 0-4 heteroatoms, independently selected from the group consisting of N, O and S, which is unsubstituted or mono-, di- or trisubstituted by R 4 ,

R 2 is linear or branched alkyl having 1-10 C atoms which is unsubstituted or mono-, di- or trisubstituted by R 4 and in which 1-4 C atoms may be replaced, independently of one another, by O, S, SO, SO 2 , NH, NCH 3 , —OCO—, —NHCONH—, —NHCO—, —NR 5 SO 2 R 6 —, —COO—, —CONH—, —NCH 3 CO—, —CONCH 3 —, —C≡C— groups and/or —CH═CH— groups, and/or 1-10 H atoms may be replaced by F and/or Cl, or cyclic alkyl having 3-7 C atoms which is unsubstituted or mono-, di- or trisubstituted by R 4 and in which 1-4 C atoms may be replaced, independently of one another, by O, S, SO, SO 2 , NH, NCH 3 , —OCO—, —NHCONH—, —NHCO—, —NR 5 SO 2 R 6 —, —COO—, —CONH—, —NCH 3 CO—, —CONCH 3 —, —C≡C— groups and/or by —CH═CH— groups and/or 1-11 H atoms may be replaced by F and/or Cl, or mono- or bicyclic heteroaryl, heterocyclyl, aryl or cyclic alkylaryl containing 3 to 14 carbon atoms and 0-4 heteroatoms, independently selected from the group consisting of N, O and S, which is unsubstituted or mono-, di- or trisubstituted by R 4 ,

R 3 is linear or branched alkyl or O-alkyl having 1-6 C atoms or cyclic alkyl having 3-6 C atoms, which is unsubstituted or mono-, di- or trisubstituted by H, ═S, ═NH, ═O, OH, cyclic alkyl having 3-6 C atoms, COOH, Hal, NH 2 , SO 2 CH 3 , SO 2 NH 2 , CN, CONH 2 , NHCOCH 3 , NHCONH 2 or NO 2 ,

R 4 is H, R 5 , ═S, ═NR 5 , ═O, OH, COOH, Hal, NH 2 , SO 2 CH 3 , SO 2 NH 2 , CN, CON H 2 , NHCOCH 3 , NHCONH 2 , NO 2 , or linear or branched alkyl having 1-10 C atoms which is unsubstituted or mono-, di- or trisubstituted by R 5 and in which 1-4 C atoms may be replaced, independently of one another, by O, S, SO, SO 2 , NH, NCH 3 , —OCO—, —NHCONH—, —NHCO—, —NR 5 SO 2 R 6 —, —COO—, —CONH—, —NCH 3 CO—, —CONCH 3 —, —C≡C— groups and/or —CH═CH— groups, and/or 1-10 H atoms may be replaced by F and/or Cl, or mono- or bicyclic cyclic alkyl having 3-7 C atoms which is unsubstituted or mono-, di- or trisubstituted by R 5 and in which 1-4 C atoms may be replaced, independently of one another, by O, S, SO, SO 2 , NH, NCH 3 , —OCO—, —NHCONH—, —NHCO—, —NRSO 2 R 4 —, —COO—, —CONH—, —NCH 3 CO—, —CONCH 3 —, —C≡C— groups and/or by —CH═CH— groups and/or 1-10 H atoms may be replaced by F and/or Cl, or mono- or bicyclic heteroaryl, heterocyclyl, aryl or cyclic alkylaryl containing 3 to 14 carbon atoms and 0-4 heteroatoms, independently selected from the group consisting of N, O and S, which is unsubstituted or mono-, di- or trisubstituted by R 5 ,

R 5 , R 6 are independently of one another ═S, ═NH, ═O, OH, COOH, Hal, NH 2 , SO 2 CH 3 , SO 2 NH 2 , CN, CONH 2 , NHCOCH 3 , NHCONH 2 , NO 2 or linear or branched alkyl having 1-10 C atoms in which 1-4 C atoms may be replaced, independently of one another, by O, S, SO, SO 2 , NH, NCH 3 , —OCO—, —NHCONH—, —NHCO—, —COO—, —CONH—, —NCH 3 CO—, —CONCH 3 —, —C≡C— groups and/or —CH═CH— groups, and/or 1-10 H atoms may be replaced by F and/or Cl,

Hal is F, C, Br, or I,

or a physiologically acceptable salt, derivative, solvate, prodrug r stereoisomer thereof.

2. The compound according to claim 1 , wherein

R 1 is linear or branched alkyl having 1-10 C atoms which is unsubstituted or mono-, di- or trisubstituted by R 4 and in which 1-4 C atoms may be replaced, independently of one another, by O, S, SO, SO 2 , NH, NCH 3 , —OCO—, —NHCONH—, —NHCO—, —NR 5 SO 2 R 6 —, —COO—, —CONH—, —NCH 3 CO—, —CONCH 3 —, —C≡C— groups and/or —CH═CH— groups, and/or 1-10 H atoms may be replaced by F and/or Cl, or one of the following structures:

which is unsubstituted or mono-, di- or trisubstituted with R 4 .

3. The compound according to claim 1 , wherein

Q is CH or N, and

Y is CH.

4. The compound according to claim 1 , wherein R 2 is one of the following structures:

which is unsubstituted or mono-, di- or trisubstituted with R 5 .

5. The compound according to claim 1 , wherein

R 3 one of the following structures

6. The compound according to claim 1 , wherein

R 3 is OMe.

7. A compound selected from the group consisting of:

No.

IUPAC-Name

1

N-[8-methoxy-5-(oxan-4-yl)quinoxalin-2-yl]-2-oxa-7-

azaspiro[4.4]nonane-7-carboxamide

2

4-hydroxy-N-[8-methoxy-5-(pyridin-4-yl)quinoxalin-

2-yl]-4-methylpiperidine-1-carboxamide

3

3-hydroxy-N-[8-methoxy-5-(oxan-4-yl)quinoxalin-2-

yl]-3-methylpyrrolidine-1-carboxamide

4

N-[8-methoxy-5-(oxan-4-yl)quinoxalin-2-yl]-2-methyl-

1,3-oxazole-4-carboxamide

5

4-(hydroxymethyl)-N-[8-methoxy-5-(oxan-4-yl)quinoxalin-

2-yl]-4-methylpiperidine-1-carboxamide

6

N-[8-methoxy-5-(oxan-4-yl)quinoxalin-2-yl]-2,2-dioxo-

2lambda6-thia-6-azaspiro[3.3]heptane-6-carboxamide

7

6-methoxy-N-[8-methoxy-5-(oxan-4-yl)quinoxalin-2-

yl]pyridazine-3-carboxamide

8

N-[8-methoxy-5-(oxan-4-yl)quinoxalin-2-yl]-1-(2-

methoxyethyl)-1H-pyrazole-4-carboxamide

9

4-hydroxy-N-(8-methoxy-5-phenylquinoxalin-2-yl)-

4-(prop-2-yn-1-yl)piperidine-1-carboxamide

10

3-hydroxy-N-(8-methoxy-5-phenylquinoxalin-2-yl)-3-

methylpyrrolidine-1-carboxamide

11

4-(hydroxymethyl)-N-(8-methoxy-5-phenylquinoxalin-2-

yl)-4-methylpiperidine-1-carboxamide

12

N-(8-methoxy-5-phenylquinoxalin-2-yl)-8-oxa-2-

azaspiro[4.5]decane-2-carboxamide

13

N-(8-methoxy-5-phenylquinoxalin-2-yl)-2-oxa-7-

azaspiro[4.4]nonane-7-carboxamide

14

N-(8-methoxy-5-phenylquinoxalin-2-yl)-2,2-dioxo-

2lambda6-thia-6-azaspiro[3.3]heptane-6-carboxamide

15

4-Hydroxy-4-methyl-piperidine-1-carboxylic acid (5-methoxy-

8-phenyl-pyrido[3,4-b]pyrazin-3-yl)-amide

16

3-Hydroxy-3-methyl-pyrrolidine-1-carboxylic acid (5-methoxy-

8-phenyl-pyrido[3,4-b]pyrazin-3-yl)-amide

17

4-Hydroxymethyl-4-methyl-piperidine-1-carboxylic acid (5-

methoxy-8-phenyl-pyrido[3,4-b]pyrazin-3-yl)-amide

18

N-[8-methoxy-5-(oxan-4-yl)quinoxalin-2-yl]-8-oxa-2-

azaspiro[4.5]decane-2-carboxamide

19

N-[8-methoxy-5-(oxan-4-yl)quinoxalin-2-yl]acetamide

20

2,2,2-trifluoro-N-[8-methoxy-5-(oxan-4-yl)quinoxalin-2-

yl]acetamide

21

4-Dimethylaminomethyl-N-(5-methoxy-8-phenyl-

pyrido[3,4-b]pyrazin-3-yl)-benzamide

22

4-Hydroxy-4-prop-2-ynyl-piperidine-1-carboxylic acid (5-methoxy-

8-phenyl-pyrido[3,4-b]pyrazin-3-yl)-amide

23

4-Methoxymethyl-N-(5-methoxy-8-phenyl-pyrido[3,4-b]pyrazin-

3-yl)-benzamide

24

1-(2-Methoxy-ethyl)-1H-pyrazole-4-carboxylic acid (5-methoxy-

8-phenyl-pyrido[3,4-b]pyrazin-3-yl)-amide

25

6-hydroxy-N-[8-methoxy-5-(oxan-4-yl)quinoxalin-2-yl]pyridazine-

4-carboxamide

26

8-methoxy-5-(oxan-4-yl)quinoxalin-2-amine

27

(3S)-3-hydroxy-N-[8-methoxy-5-(oxan-4-yl)quinoxalin-2-yl]-3-

methylpyrrolidine-1-carboxamide

28

(3R)-3-hydroxy-N-[8-methoxy-5-(oxan-4-yl)quinoxalin-2-yl]-3-

methylpyrrolidine-1-carboxamide

29

4-hydroxy-N-[8-methoxy-5-(2-methylphenyl)quinoxalin-2-yl]-4-

methylpiperidine-1-carboxamide

30

N-(8-methoxy-5-phenylquinoxalin-2-yl)-1-(2-methoxyethyl)-1H-

pyrazole-4-carboxamide

31

N-(8-methoxy-5-phenylquinoxalin-2-yl)-2-methyl-1,3-oxazole-4-

carboxamide

32

N-(8-methoxy-5-phenylquinoxalin-2-yl)-1-methyl-1H-pyrazole-4-

carboxamide

33

N-(8-methoxy-5-phenylquinoxalin-2-yl)cyclopropanecarboxamide

34

N-(8-methoxy-5-phenylquinoxalin-2-yl)-1-methyl-1H-pyrazole-

5-carboxamide

35

N-(8-methoxy-5-phenylquinoxalin-2-yl)-1,3-thiazole-5-carboxamide

36

N-(8-methoxy-5-phenylquinoxalin-2-yl)-2-methyl-1,3-thiazole-

5-carboxamide

37

N-(8-methoxy-5-phenylquinoxalin-2-yl)-4H-1,2,4-triazole-3-

carboxamide

38

N-[5-(4-fluorophenyl)-8-methoxyquinoxalin-2-yl]-4-hydroxy-4-

methylpiperidine-1-carboxamide

39

4-Hydroxy-4-methyl-piperidine-1-carboxylic acid [5-methoxy-8-

(tetrahydro-pyran-4-yl)-pyrido[3,4-b]pyrazin-3-yl]-amide

40

N-[8-methoxy-5-(oxan-4-yl)quinoxalin-2-

yl]cyclopropanecarboxamide

41

4-Hydroxy-4-methyl-piperidine-1-carboxylic acid [8-methoxy-5-

(6-methyl-pyridazin-3-yl)-quinoxalin-2-yl]-amide

42

1-(2-Methoxy-ethyl)-1H-pyrazole-4-carboxylic acid [8-methoxy-

5-(6-methyl-pyridazin-3-yl)-quinoxalin-2-yl]-amide

43

1-(2-Methoxy-ethyl)-1H-pyrazole-4-carboxylic acid (8-methoxy-5-

pyridin-4-yl-quinoxalin-2-yl)-amide

44

1-(2-Methoxy-ethyl)-1H-pyrazole-4-carboxylic acid [5-methoxy-8-

(tetrahydro-pyran-4-yl)-pyrido[3,4-b]pyrazin-3-yl]-amide

45

Isoxazole-4-carboxylic acid (5-methoxy-8-phenyl-

pyrido[3,4-b]pyrazin-3-yl)-amide

46

4-Hydroxymethyl-4-methyl-piperidine-1-carboxylic acid [8-

methoxy-5-(tetrahydro-pyran-4-yl)-quinoxalin-2-yl]-amide

47

3-Hydroxy-3-methyl-pyrrolidine-1-carboxylic acid [5-methoxy-8-

(tetrahydro-pyran-4-yl)-pyrido[3,4-b]pyrazin-3-yl]-amide

48

4-Hydroxy-4-methyl-piperidine-1-carboxylic acid [5-(2-fluoro-

phenyl)-8-methoxy-quinoxalin-2-yl]-amide

49

4-Hydroxy-4-methyl-piperidine-1-carboxylic acid [5-(4-fluoro-

phenyl)-8-methoxy-quinoxalin-2-yl]-amide

50

4-Hydroxy-4-methyl-piperidine-1-carboxylic acid [5-(3-fluoro-

phenyl)-8-methoxy-quinoxalin-2-yl]-amide

51

4-Hydroxy-4-methyl-piperidine-1-carboxylic acid [8-methoxy-

5-(2-oxa-7-aza-spiro[4.4]non-7-yl)-quinoxalin-2-yl]-amide

52

4-Hydroxy-4-methyl-piperidine-1-carboxylic acid (8-methoxy-5-

pyridin-3-yl-quinoxalin-2-yl)-amide

53

4-Hydroxy-4-methyl-piperidine-1-carboxylic acid (5-azepan-1-yl-

8-methoxy-quinoxalin-2-yl)-amide

54

4-Hydroxy-4-methyl-piperidine-1-carboxylic acid (8-methoxy-5-

phenyl-pyrido[3,4-b]pyrazin-2-yl)-amide

55

Isoxazole-4-carboxylic acid [5-methoxy-8-(tetrahydro-pyran-4-yl)-

pyrido[3,4-b]pyrazin-3-yl]-amide

56

1-Methyl-1H-pyrazole-4-carboxylic acid [8-methoxy-5-(tetrahydro-

pyran-4-yl)-quinoxalin-2-yl]-amide

57

5-Methyl-isoxazole-4-carboxylic acid [8-methoxy-5-(tetrahydro-

pyran-4-yl)-quinoxalin-2-yl]-amide

58

5-Cyclopropyl-isoxazole-4-carboxylic acid [8-methoxy-5-

(tetrahydro-pyran-4-yl)-quinoxalin-2-yl]-amide

59

1-(2-Methoxy-ethyl)-1H-[1,2,3]triazole-4-carboxylic acid [8-

methoxy-5-(tetrahydro-pyran-4-yl)-quinoxalin-2-yl]-amide

60

1-Methyl-1H-[1,2,3]triazole-4-carboxylic acid [8-methoxy-5-

(tetrahydro-pyran-4-yl)-quinoxalin-2-yl]-amide

61

1-Cyano-cyclopropanecarboxylic acid [8-methoxy-5-(tetrahydro-

pyran-4-yl)-quinoxalin-2-yl]-amide

62

Cyclopropanesulfonic acid [8-methoxy-5-(tetrahydro-pyran-4-yl)-

quinoxalin-2-yl]-amide

63

[8-Methoxy-5-(tetrahydro-pyran-4-yl)-quinoxalin-2-yl]-carbamic

acid isopropyl ester

64

2-Methyl-2H-pyrazole-3-carboxylic acid [8-methoxy-5-(tetrahydro-

pyran-4-yl)-quinoxalin-2-yl]-amide

65

Thiazole-5-carboxylic acid [8-methoxy-5-(tetrahydro-pyran-4-yl)-

quinoxalin-2-yl]-amide

66

2-Methyl-thiazole-5-carboxylic acid [8-methoxy-5-(tetrahydro-

pyran-4-yl)-quinoxalin-2-yl]-amide

67

1H-[1,2,4]Triazole-3-carboxylic acid [8-methoxy-5-(tetrahydro-

pyran-4-yl)-quinoxalin-2-yl]-amide

68

2,3-Dimethyl-3H-imidazole-4-sulfonic acid [8-methoxy-5-

(tetrahydro-pyran-4-yl)-quinoxalin-2-yl]-amide

69

Imidazo[1,2-a]pyrazine-2-carboxylic acid [8-methoxy-5-(tetrahydro-

pyran-4-yl)-quinoxalin-2-yl]-amide

70

Azetidine-3-carboxylic acid [8-methoxy-5-(tetrahydro-pyran-4-yl)-

quinoxalin-2-yl]-amide

71

Azetidine-3-carboxylic acid (8-methoxy-5-phenyl-quinoxalin-

2-yl)-amide

72

Imidazo[1,2-a]pyrazine-2-carboxylic acid (8-methoxy-5-phenyl-

quinoxalin-2-yl)-amide

73

2,3-Dimethyl-3H-imidazole-4-sulfonic acid (8-methoxy-5-phenyl-

quinoxalin-2-yl)-amide

74

(8-Methoxy-5-phenyl-quinoxalin-2-yl)-carbamic acid isopropyl ester

75

Cyclopropanesulfonic acid (8-methoxy-5-phenyl-quinoxalin-2-yl)-

amide

76

1-Cyano-cyclopropanecarboxylic acid (8-methoxy-5-phenyl-

quinoxalin-2-yl)-amide

77

1-Methyl-1H-[l,2,3]triazole-4-carboxylic acid (8-methoxy-5-phenyl-

quinoxalin-2-yl)-amide

78

1-(2-Methoxy-ethyl)-1H[1,2,3]triazole-4-carboxylic acid (8-

methoxy-5-phenyl-quinoxalin-2-yl)-amide

79

5-Cyclopropyl-isoxazole-4-carboxylic acid (8-methoxy-5-phenyl-

quinoxalin-2-yl)-amide

80

5-Methyl-isoxazole-4-carboxylic acid (8-methoxy-5-phenyl-

quinoxalin-2-yl)-amide

81

1-Methyl-1H-pyrazole-4-carboxylic acid (8-methoxy-5-phenyl-

quinoxalin-2-yl)-amide

82

6-Oxo-1,6-dihydro-pyridazine-4-carboxylic acid (8-methoxy-5-

phenyl-quinoxalin-2-yl)-amide

83

4-Hydroxy-4-methyl-piperidine-1-carboxylic acid (5-butyl-8-

methoxy-quinoxalin-2-yl)-amide

84

4-Hydroxy-4-methyl-piperidine-1-carboxylic acid [8-methoxy-

5-(1-propyl-cyclopropyl)-quinoxalin-2-yl]-amide

85

4-Hydroxy-4-methyl-piperidine-1-carboxylic acid [8-methoxy-

5-(1-methoxymethyl-cyclopropyl)-quinoxalin-2-yl]-amide

86

4-Hydroxy-4-methyl-piperidine-1-carboxylic acid [5-(3-amino-

phenyl)-8-methoxy-quinoxalin-2-yl]-amide

87

4-Hydroxy-4-methyl-piperidine-1-carboxylic acid (8-methoxy-5-

pyridin-2-yl-quinoxalin-2-yl)-amide

88

4-Hydroxy-4-methyl-piperidine-1-carboxylic acid (8-methoxy-5-

o-tolyl-quinoxalin-2-yl)-amide

89

1-Cyano-cyclopropanecarboxylic acid (5-methoxy-8-phenyl-

pyrido[3,4-b]pyrazin-3-yl)-amide

90

Cyclopropanecarboxylic acid (5-methoxy-8-phenyl-pyrido[3,4-

b]pyrazin-3-yl)-amide

91

N-[8-methoxy-5-(oxan-4-yl)quinoxalin-2-yl]-2-oxa-7-

azaspiro[4.4]nonane-7-carboxamide

92

4-hydroxy-N-[8-methoxy-5-(pyridin-4-yl)quinoxalin-2-yl]-4-

methylpiperidine-1-carboxamide

93

3-hydroxy-N-[8-methoxy-5-(oxan-4-yl)quinoxalin-2-yl]-3-

methylpyrrolidine-1-carboxamide

94

N-[8-methoxy-5-(oxan-4-yl)quinoxalin-2-yl]-2-methyl-1,3-

oxazole-4-carboxamide

95

4-(hydroxymethyl)-N-[8-methoxy-5-(oxan-4-yl)quinoxalin-2-

yl]-4-methylpiperidine-1-carboxamide

96

N-[8-methoxy-5-(oxan-4-yl)quinoxalin-2-yl]-2,2-dioxo-2lambda6-

thia-6-azaspiro[3.3]heptane-6-carboxamide

97

6-methoxy-N-[8-methoxy-5-(oxan-4-yl)quinoxalin-2-yl]pyridazine-

3-carboxamide

98

N-[8-methoxy-5-(oxan-4-yl)quinoxalin-2-yl]-1-(2-methoxyethyl)-

1H-pyrazole-4-carboxamide

99

4-hydroxy-N-(8-methoxy-5-phenylquinoxalin-2-yl)-4-(prop-2-yn-1-

yl)piperidine-1-carboxamide

100

3-hydroxy-N-(8-methoxy-5-phenylquinoxalin-2-yl)-3-

methylpyrrolidine-1-carboxamide

101

4-(hydroxymethyl)-N-(8-methoxy-5-phenylquinoxalin-2-yl)-4-

methylpiperidine-1-carboxamide

102

N-(8-methoxy-5-phenylquinoxalin-2-yl)-8-oxa-2-

azaspiro[4.5]decane-2-carboxamide

103

4-Hydroxy-4-prop-2-ynyl-piperidine-1-carboxylic acid [5-methoxy-

8-(tetrahydro-pyran-4-yl)-pyrido[3,4-b]pyrazin-3-yl]-amide

104

4-Hydroxymethyl-4-methyl-piperidine-1-carboxylic acid [5-

methoxy-8-(tetrahydro-pyran-4-yl)-pyrido[3,4-b]pyrazin-3-yl]-amide

105

N-(8-methoxy-5-phenylquinoxalin-2-yl)-2-methyl-1,3-oxazole-5-

carboxamide

106

Cyclopropanecarboxylic acid [5-methoxy-8-(tetrahydro-pyran-4-

yl)-pyrido[3,4-b]pyrazin-3-yl]-amide

107

N-(8-butyl-5-methoxyquinoxalin-2-yl)-4-hydroxy-4-

methylpiperidine-1-carboxamide

108

N-(5-butyl-8-methoxyquinoxalin-2-yl)-4-hydroxy-4-

methylpiperidine-1-carboxamide

109

N-[5-(3,6-dihydro-2H-pyran-4-yl)-8-methoxyquinoxalin-2-yl]-4-

hydroxy-4-methylpiperidine-1-carboxamide

110

N-[8-(3-fluorophenyl)-5-methoxyquinoxalin-2-yl]-4-hydroxy-4-

methylpiperidine-1-carboxamide

111

N-[8-(2-fluorophenyl)-5-methoxyquinoxalin-2-yl]-4-hydroxy-4-

methylpiperidine-1-carboxamide

112

4-hydroxy-N-[5-methoxy-8-(pyridin-3-yl)quinoxalin-2-yl]-4-

methylpiperidine-1-carboxamide

113

6-methoxy-N-(8-methoxy-5-phenylquinoxalin-2-yl)pyridazine-

3-carboxamide

114

4-hydroxy-N-(8-methoxy-5-{1-[(pyridin-2-yl)methyl]-1H-pyrazol-

4-yl}quinoxalin-2-yl)-4-methylpiperidine-1-carboxamide

115

4-{2-[(4-hydroxy-4-methylpiperidine-1-carbonyl)amino]-8-

methoxyquinoxalin-5-yl}-N-methylpyridine-2-carboxamide

116

tert-butyl 3-(4-{2-[(4-hydroxy-4-methylpiperidine-1-

carbonyl)amino]-8-methoxyquinoxalin-5-yl}-1H-pyrazol-1-

yl)azetidine-1-carboxylate

117

4-hydroxy-N-{8-methoxy-5-[3-(2-methoxyethoxy)phenyl]quinoxalin-

2-yl}-4-methylpiperidine-1-carboxamide

118

4-hydroxy-N-(8-methoxy-5-{3-[(2-

methoxyethoxy)methyl]phenyl}quinoxalin-2-yl)-4-methylpiperidine-

1-carboxamide

119

4-hydroxy-N-(8-methoxy-5-{1-[2-(2-methoxyethoxy)ethyl]-1H-

pyrazol-4-yl}quinoxalin-2-yl)-4-methylpiperidine-1-carboxamide

120

N-[5-(2-fluorophenyl)-8-methoxyquinoxalin-2-

yl]cyclopropanecarboxamide

121

N-[8-methoxy-5-(pyridin-3-yl)quinoxalin-2-

yl]cyclopropanecarboxamide

122

N-[5-(azepan-1-yl)-8-methoxyquinoxalin-2-

yl]cyclopropanecarboxamide

123

N-[5-(2,3-difluorophenyl)-8-methoxyquinoxalin-2-

yl]cyclopropanecarboxamide

124

N-[5-(2,5-difluorophenyl)-8-methoxyquinoxalin-2-

yl]cyclopropanecarboxamide

125

N-[5-(2,3-difluorophenyl)-8-methoxyquinoxalin-2-yl]-2-methyl-1,3-

oxazole-5-carboxamide

126

N-[5-(4-fluorophenyl)-8-methoxyquinoxalin-2-

yl]cyclopropanecarboxamide

127

N-[8-methoxy-5-(1,2,3,6-tetrahydropyridin-4-yl)quinoxalin-2-

yl]cyclopropanecarboxamide

128

N-[5-(2,5-difluorophenyl)-8-methoxyquinoxalin-2-yl]-2-methyl-

1,3-oxazole-5-carboxamide

129

N-[5-(2-fluorophenyl)-8-methoxyquinoxalin-2-yl]-2-methyl-1,3-

oxazole-5-carboxamide

130

N-[8-methoxy-5-(oxan-4-yl)quinoxalin-2-yl]-2-methyl-1,3-oxazole-

5-carboxamide

131

N-[5-(4-fluorophenyl)-8-methoxyquinoxalin-2-yl]-2-methyl-1,3-

oxazole-5-carboxamide

132

N-[5-(3,6-dihydro-2H-pyran-4-yl)-8-methoxyquinoxalin-2-yl]-2-

methyl-1,3-oxazole-5-carboxamide

133

N-{5-[1-(azetidin-3-yl)-1H-pyrazol-4-yl]-8-methoxyquinoxalin-2-

yl}-4-hydroxy-4-methylpiperidine-1-carboxamide

134

N-[5-(3,6-dihydro-2H-pyran-4-yl)-8-methoxyquinoxalin-2-yl]-2-

methyl-1,3-thiazole-5-carboxamide

135

N-[5-(3,6-dihydro-2H-pyran-4-yl)-8-methoxyquinoxalin-2-yl]-1-

methyl-1H-pyrazole-4-carboxamide

136

N-[5-(3,6-dihydro-2H-pyran-4-yl)-8-methoxyquinoxalin-2-yl]-1,2-

thiazole-4-carboxamide

137

1-amino-N-[5-(3,6-dihydro-2H-pyran-4-yl)-8-methoxyquinoxalin-

2-yl]cyclopropane-1-carboxamide

138

N-[8-methoxy-5-(pyridin-3-yl)quinoxalin-2-yl]-2-methyl-1,3-

oxazole-5-carboxamide

139

2-amino-N-[5-(3,6-dihydro-2H-pyran-4-yl)-8-methoxyquinoxalin-

2-yl]-1,3-thiazole-4-carboxamide

140

N-[5-(3,6-dihydro-2H-pyran-4-yl)-8-methoxyquinoxalin-2-yl]-5-

(oxolan-3-yl)-1,3-thiazole-2-carboxamide

141

N-[5-(2,5-dihydrofuran-3-yl)-8-methoxyquinoxalin-2-

yl]cyclopropanecarboxamide

142

5-(aminomethyl)-N-[5-(3,6-dihydro-2H-pyran-4-yl)-8-

methoxyquinoxalin-2-yl]furan-3-carboxamide

143

ethyl 5-({[5-(3,6-dihydro-2H-pyran-4-yl)-8-methoxyquinoxalin-2-

yl]carbamoyl}amino)-1,3,4-thiadiazole-2-carboxylate

144

N′1-[5-(3,6-dihydro-2H-pyran-4-yl)-8-methoxyquinoxalin-2-yl]-

N1,N1-dimethylcyclopropane-1,1-dicarboxamide

145

N-[5-(3,6-dihydro-2H-pyran-4-yl)-8-methoxyquinoxalin-2-yl]-1-

[(dimethylamino)methyl]cyclopropane-1-carboxamide

146

N-[5-(3,6-dihydro-2H-pyran-4-yl)-8-methoxyquinoxalin-2-yl]-5-

methyl-1,3,4-thiadiazole-2-carboxamide

147

N-{8-methoxy-5-[3-(2-methoxyethoxy)phenyl]quinoxalin-2-

yl}cyclopropanecarboxamide

148

N-{8-methoxy-5-[3-(2-methoxyethoxy)phenyl]quinoxalin-2-yl}-

2-methyl-1,3-oxazole-5-carboxamide

149

N′1-(8-methoxy-5-phenylquinoxalin-2-yl)-N1,N1-

dimethylcyclopropane-1,1-dicarboxamide

150

1-[(dimethylamino)methyl]-N-(8-methoxy-5-phenylquinoxalin-2-

yl)cyclopropane-1-carboxamide

151

N-{8-methoxy-5-[3-(2-methoxyethoxy)phenyl]quinoxalin-2-yl}-

2-methyl-1,3-thiazole-5-carboxamide

152

N-{8-methoxy-5-[3-(2-methoxyethoxy)phenyl]quinoxalin-2-yl}-

5-methyl-1,3,4-thiadiazole-2-carboxamide

153

4-hydroxy-N-{8-methoxy-5-[1-(pyridin-2-yl)-1H-pyrazol-4-

yl]quinoxalin-2-yl}-4-methylpiperidine-1-carboxamide

154

N-[8-methoxy-5-(6-methylpyridazin-3-yl)quinoxalin-2-yl]-2-

methyl-1,3-oxazole-5-carboxamide

155

N-[8-methoxy-5-(2-methoxypyrimidin-5-yl)quinoxalin-2-yl]-

2-methyl-1,3-oxazole-5-carboxamide

156

N-[8-methoxy-5-(2-methoxypyrimidin-5-yl)quinoxalin-2-

yl]cyclopropanecarboxamide

157

N-{5-[1-(difluoromethyl)-1H-pyrazol-4-yl]-8-methoxyquinoxalin-2-

yl}-2-methyl-1,3-oxazole-5-carboxamide

158

N-{5-[1-(difluoromethyl)-1H-pyrazol-4-yl]-8-methoxyquinoxalin-2-

yl}-4-hydroxy-4-methylpiperidine-1-carboxamide

159

N-[5-(3,6-dihydro-2H-pyran-4-yl)-8-methoxyquinoxalin-2-yl]-1H-

imidazole-5-carboxamide

160

N-(8-methoxy-5-phenylquinoxalin-2-yl)-1H-imidazole-5-

carboxamide

161

N-[8-methoxy-5-(1,4-oxazepan-4-yl)quinoxalin-2-

yl]cyclopropanecarboxamide

or a physiologically acceptable salt, derivative, solvate, prodrug or stereoisomer thereof.

8. A process for the preparation of a compound of the formula I according to claim 1 , comprising

a) a compound of the formula II undergoes a nitration reaction, followed by a reduction to give a compound of formula IV, a compound of formula IV is cyclized to give a compound of formula V, a compound of formula V is chlorinated followed by a copper catalyzed amination reaction to give compound VII, a compound of formula VII is reacted in a Suzuki type reaction to a compound of formula VIII by a catalyst and base, a compound of formula VIII is converted to a compound of formula I by amidation or carbamide formation conditions wherein Q, Y, R 1 , R 2 and R 3 have the meanings as disclosed for the compound of formula I,

b) a compound of the formula III is reacted with a boronic ester or acid under Suzuki-type reaction conditions to give a compound of formula IX or reacted with an amine in a nucleophilic substitution reaction under increased temperature to form a compound of formula IX, a compound of formula IX is reduced to a compound of formula X and cyclized to a compound of formula XI, a compound of formula XI is chlorinated followed by copper catalyzed amination to give compound VIII and finally compound VIII is reacted to a compound of formula I under amidation or carbamide formation conditions and wherein Q, Y, R 1 , R 2 and R 3 have the meanings as disclosed for the compound of formula I,

c) a compound of the formula XIII is reacted with a boronic ester or acid under Suzuki-type reaction conditions to give a compound of formula XIV, a compound of formula XIV is reduced to a compound of formula X and cyclized to a compound of formula XI, a compound of formula XI is tosylated followed by metal catalyzed amination to give compound VIII and finally compound VIII is reacted to a compound of formula I under amidation or carbamide formation conditions and wherein Q, Y, R 1 , R 2 and R 3 have the meanings as disclosed for the compound of formula I,

d) a base of a compound of formula I is converted into one of its salts by treatment with an acid, or

e) an acid of a compound of formula I is converted into one of its salts by treatment with a base.

9. A method for inhibiting an adenosine A 2A and/or A 2B receptor, comprising administering to said receptor a compound of claim 1 or a physiologically acceptable salt, derivative, solvate, prodrug or stereoisomer thereof.

10. A pharmaceutical composition comprising at least one compound according to claim 1 and/or a physiologically acceptable salt, derivative, solvate, prodrug or stereoisomer thereof and at least one excipient and/or adjuvant.

11. The pharmaceutical composition according to claim 10 , further comprising at least one further pharmaceutically active compound.

12. A process for the preparation of a pharmaceutical composition according to claim 10 , comprising bringing a compound of formula I and/or one of its physiologically acceptable salts, derivatives, solvates, prodrugs or stereoisomers thereof into a dosage form together with a solid, liquid or semi-liquid excipient or adjuvant.

13. A method for the treatment and/or prophylaxis of a physiological and/or pathophysiological state, comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition according to claim 10 , wherein an adenosine A 2A and/or A 2B receptor is inhibited.

14. A method for the treatment and/or prophylaxis of a hyperproliferative or infectious disease or disorder, comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition according to claim 10 , wherein an adenosine A 2A and/or A 2B receptor is inhibited.

15. The method according to claim 14 , wherein the hyperproliferative disease or disorder is cancer.

16. The method according to claim 15 , wherein the cancer is selected from the group consisting of acute lymphocytic leukemia, chronic lymphocytic leukemia, acute granulocytic leukemia, adrenal cortex cancer, bladder cancer, brain cancer, breast cancer, cervical cancer, cervical hyperplasia, cervical cancer, chorio cancer, chronic granulocytic leukemia, chronic lymphocytic leukemia, colon cancer, endometrial cancer, esophageal cancer, essential thrombocytosis, genitourinary carcinoma, glioma, glioblastoma, hairy cell leukemia, head and neck carcinoma, Hodgkin's disease, Kaposi's sarcoma, lung carcinoma, lymphoma, malignant carcinoid carcinoma, malignant hypercalcemia, malignant melanoma, malignant pancreatic insulinoma, medullary thyroid carcinoma, melanoma, multiple myeloma, mycosis fungoides, myeloid leukemia, lymphocytic leukemia, neuroblastoma, non-Hodgkin's lymphoma, non-small cell lung cancer, osteogenic sarcoma, ovarian carcinoma, pancreatic carcinoma, polycythemia vera, primary brain carcinoma, primary macroglobulinemia, prostatic cancer, renal cell cancer, rhabdomyosarcoma, skin cancer, small-cell lung cancer, soft-tissue sarcoma, squamous cell cancer, stomach cancer, testicular cancer, thyroid cancer and Wilms' tumor.

17. The method according to claim 14 , wherein the hyperproliferative disease or disorder is selected from the group consisting of age-related macular degeneration, Crohn's disease, cirrhosis, chronic inflammatory-related disorders, proliferative diabetic retinopathy, proliferative vitreoretinopathy, retinopathy of prematurity, granulomatosis, immune hyperproliferation associated with organ transplantation, immune hyperproliferation associated with tissue transplantation, an immunoproliferative disease, an immunoproliferative disorder, inflammatory bowel disease, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, vascular hyperproliferation secondary to retinal hypoxia and vasculitis.

18. The method according to claim 14 , wherein the infectious disease or disorder is selected from the group consisting of

a) virally induced infectious diseases which are caused by retroviruses, hepadnaviruses, herpesviruses, flaviviridae and/or adenoviruses wherein the retroviruses are selected from the group consisting of lentiviruses and oncoretroviruses, wherein the lentivirus is selected from the group consisting of HIV-1, HIV-2, FIV, BIV, SIVs, SHIV, CAEV, VMV and EIAV and the oncoretrovirus is selected from the group consisting of HTLV-I, HTLV-II and BLV, the hepadnavirus is selected from the group consisting of HBV, GSHV and WHV, the herpesivirus is selected from the group consisting of HSV I, HSV II, EBV, VZV, HCMV and HHV 8 and the flaviviridae is selected from the group consisting of HCV, West nile and Yellow Fever,

b) bacterial infectious diseases which are caused by Gram-positive bacteria wherein the Gram-positive bacteria are selected from the group consisting of methicillin-susceptible staphylococci, methicillin-resistant staphylococci, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus haemolyticus, Staphylococcus hominis, Staphylococcus saprophyticus , coagulase-negative staphylococci, glycopeptides-intermediate susceptible Staphylococcus aureus , penicillin-susceptible streptococci, penicillin-resistant streptococci, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus avium, Streptococcus bovis, Streptococcus lactis, Streptococcus sanguis , Streptococci Group C, Streptococci Group G, viridans streptococci, enterococci, vancomycin susceptible strains, vancomycin-resistant strains, Enterococcus faecalis, Enterococcus faecium, Clostridium difficile, Listeria monocytogenes, Corynebacterium jeikeium, Chlamydia spp, C. pneumoniae and Mycobacterium tuberculosis,

c) bacterial infectious diseases which are caused by Gram-negative bacteria wherein the Gram-negative bacteria are selected from the group consisting of the Genus Enterobacteriacae, Escherichia spp., Escherichia coli, Klebsiella spp., Enterobacter spp., Citrobacter spp., Serratia spp., Proteus spp., Providencia spp., Salmonella spp., Shigella spp., the genus Pseudomonas, P. aeruginosa, Moraxella spp., M. catarrhalis, Haemophilus spp. and Neisseria spp.,

d) infectious diseases induced by intracellular active parasites selected from the group consisting of phylum Apicomplexa, Sarcomastigophora, Trypanosoma, Plasmodia, Leishmania, Babesia, Theileria , Cryptosporidia, Sacrocystida, Amoebia, Coccidia and Trichomonadia.

19. A kit comprising separate packs of

a) a compound according to claim 1 or a physiologically acceptable salt, derivative, solvate, prodrug or stereoisomer thereof, and

b) a further pharmaceutically active compound.

20. The compound according to claim 1 or a pharmaceutically acceptable salt thereof.

21. The compound according to claim 7 or a pharmaceutically acceptable salt thereof.